Search for: "State v. Gilead Sciences, Inc." Results 21 - 40 of 68
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
30 Oct 2019, 6:23 pm by Lawrence B. Ebert
Gilead Sciences Inc., (“Gilead”)argues that the patent is also invalid for failure to meet thewritten description requirement, and that the district courterred by failing to grant JMOL on that ground as well. [read post]
11 Oct 2018, 12:57 am by Eszter Szakács
Eszter SzakácsCo-author: Zsolt Lengyel, Danubia Patent and Law Office Just a few months before the CJEU’s judgment in C-121/17 Teva UK Ltd and Others v Gilead Sciences Inc. came out a the Metropolitan Court of Budapest handed down a decision regarding Merck Sharp and Dohme Corp’s (MSD) application for an SPC re the combination of ezetimibe and rosuvastatin. [read post]
20 Jul 2008, 2:50 pm
Gilead Sciences, Inc., No. 06-4290, the three-judge panel reversed and remanded the case involving a Family and Medical Leave Act claim. [read post]
1 Apr 2014, 11:27 am by Mack Sperling
Gilead Sciences, Inc., 2014 NCBC 10 is a procedural conundrum wrapped up in arbitration issues. [read post]
17 Nov 2014, 6:50 am
Gilead Sciences, Inc., which is a big reason we cited the horrendous Murthy opinion from a couple years ago, in a case involving clinical trials that left us Dazed and Confused. [read post]
26 Jun 2015, 12:30 am
 Actually, Mr Justice Arnold had himself moved away from the idea already - he distinguished his decision in the later case of Idenix Pharmaceutical, Inc v Gilead Sciences, Inc (reported by IPKat here) in which he declined to construe a claim narrowly on the basis of the prosecution history.This did not however have any effect on the outcome - Floyd LJ otherwise endorsed Arnold J's application of the Protocol questions to likewise find that… [read post]
16 Jul 2008, 10:40 am
Gilead Sciences Inc., No. 06-4290 (7th Cir. [read post]
5 Sep 2023, 2:39 am by Courtenay C. Brinckerhoff
Cellect Strategies  Some stakeholders have been expecting a decision like Cellect since the Federal Circuit first decided that a later-granted patent can raise OTDP issues for an earlier-granted patent, in its 2014 decision in Gilead Sciences, Inc. v. [read post]
8 Jan 2016, 5:26 am
’ In re Gilead Sciences Securities Litigation, 536 F.3d 1049 (U.S. [read post]
9 May 2017, 4:42 am
Arnold J. reiterated his view (expressed previously in Teva UK Ltd v Gilead Sciences Inc [2017] EWHC 13 (Pat)) that the test in Lilly remains unclear. [read post]